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Abstract
Trichinellosis is a food-borne parasitic disease caused by round worms of the genus 
Trichinella. The majority of human outbreaks are attributed to consumption of raw 
or undercooked pork meat contaminated with T. spiralis muscle larvae. A blocking- 
transmission vaccine against trichinellosis will allow preventing swine infection and will 
contribute to disease control. In this chapter, different vaccine candidates so far devel-
oped against T. spiralis, including first-, second-, and third-generation vaccines, are dis-
cussed. Most vaccine candidates are based on a unique antigen mainly from the muscle 
larva stage, inducing with some exceptions, partial protection although a mix Th1/Th2 
immune response is elicited. Therefore, the need for identification of new antigens from 
different parasite stages focusing on infective intestinal larvae, adult, and newborn lar-
vae stages as well as the evaluation of their protective capacity in pigs is presented. The 
design of multi-epitope vaccines and the use of adjuvants or immunomodulatory mol-
ecules capable to polarize the immune response to a Th2-type-protective response are 
discussed as imperative elements of modern vaccines. Plant-based vaccines and probiot-
ics as excellent tools for vaccine development against T. spiralis are also presented as an 
attractive platform for veterinary vaccines.
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1. Introduction
Trichinellosis is a significant global zoonotic disease produced by the nematode species of 
the genus Trichinella. Trichinellosis is an emerging and reemerging disease in many countries 
[1]. In the international ranking of food-borne parasites, T. spiralis was ranked among the 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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distribution, and reproduction in any medium, provided the original work is properly cited.
top 10 [2]. T. spiralis is the best characterized member of Trichinella genus since it is highly 
infective for sylvatic and domestic animals as well as for humans. Besides, its life cycle can be 
maintained in experimental animals, providing information about host-parasite relationships 
and immunity. Infection with T. spiralis initiates when the host ingests raw or undercooked 
meat contaminated with encysted muscle larvae (ML) (Figure 1). The larvae are released from 
muscle tissue by host digestive enzymes in the stomach. Then, ML migrates to the small intes-
tine where they penetrate the intestinal mucosa and undergo four successive molts, becom-
ing mature adult worms. This intestinal phase is the first stage in the host-parasite interplay. 
At days 1 and 2 post infection, newborn larvae (NBL) are released by female adult worm 
and spread via the blood and lymphatic systems to striated muscle, where they invade the 
myofibers, develop into ML, and induce the transformation of infected cells to the nurse-cell 
complex.
T. spiralis continues to be the causative agent in most outbreaks in humans. The majority of 
outbreaks are attributed to domestic pork maintained in small farms or non-controlled out-
door backyard pigs, where poor husbandry conditions place pigs at high risk. From 1986 to 
2009, there were 65,818 cases and 42 deaths reported from 41 countries, 50% of those occurred 
in Romania, mainly during 1990–1999 [3]. In China, from 2005 to 2009, 15 outbreaks of human 
trichinellosis with 1387 cases and four deaths were recorded in three provinces of southwest-
ern China. Twelve of these 15 outbreaks were caused by the eating of raw or undercooked pork 
meat [4]. The animal health situation varies between different countries being Argentina and 
some Eastern European countries where most of the cases were reported in pigs in 2015 [5].
T. spiralis infection induces a complex host immune response against a diversity of stage-
specific antigens. Up to now, it is well known that during the intestinal phase of infection, 
the immune response involves a Th1/Th2 response with predominance of the Th2 phenotype 
characterized by the production of high levels of cytokines IL-4, IL-5, IL-9, and IL-10 as well 
as IgE, IgG1, and the mobilization of eosinophils and mast cells. Furthermore, the long-lasting 
Figure 1. Trichinella spiralis life cycle.
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infection of muscles with Trichinella reflects successful immunomodulation of the immune 
response, mainly characterized by a Th2 phenotype [6].
Despite the availability of effective and relatively safe drugs such as albendazole and meben-
dazole for trichinellosis treatment, chemotherapy has several disadvantages such as treat-
ment failure, parasite drug resistance, poor drug absorption in the intestinal lumen, and low 
bioavailability. Besides, traditional anthelminthic drugs are active against enteric stages of T. 
spiralis, but currently no anthelminthic drug has proven to be effective against the parasite 
systemic stages [7, 8]. Furthermore, serious side effects including bone marrow suppression 
and teratogenic effects are observed [7, 8].
An alternative for trichinellosis control is vaccination of livestock. Indeed, veterinary vaccines 
have already made enormous impacts not only on animal health, welfare, and production but 
also on human health [9]. Vaccines have been demonstrated to be efficient, reliable, and sus-
tainable method to control parasitic infections, and have been referred as a green solution [10].
The aim of this chapter is to update the advances so far achieved in the development of a 
transmission-blocking vaccine against trichinellosis to prevent swine infection. Trichinellosis 
vaccine would make a practical contribution to disease control, reducing the production of 
residues in meat and food chain, eliminating the risk for the consumer and in some cases to 
improve the productivity of the individual animal.
The first part of the review presents an overview of T. spiralis antigenic molecules proposed 
as first- and second-generation vaccines, discussing the need for identifying and characteriz-
ing antigenic molecules from NBL and adult worm, mainly recognized by T. spiralis-infected 
swine, administered with adjuvants or delivered by carrier systems. The second part provides 
a description of third-generation vaccines (DNA vaccines) delivered as naked DNA or by 
carrier systems. Some experimental data recently obtained by our research group using sec-
ond- and third-generation vaccines will be presented. Finally, the alternative use of adjuvants, 
multi-epitope vaccines, plants as a system to express antigenic molecules, and probiotics to 
protect against parasite infection will be discussed too.
2. First- and second-generation vaccines against trichinellosis
The biggest challenge for vaccine development is the identification of the best T. spiralis anti-
gens that elicit host-protective immunity in terms of safety and protection at the both enteral 
and systemic levels. Different antigenic preparations from different parasite stages using dif-
ferent adjuvants have been tested as vaccine candidates. Most information related to immu-
nity elicited by vaccine candidates have been mainly obtained from rodent models and only 
few studies have been performed in pigs.
2.1. First-generation vaccines
First-generation vaccines developed against trichinellosis include the use of autoclaved T. s piralis 
larvae and inactivated ML administered with complete Freund's adjuvant (CFA). These types of 
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vaccines induced in immunized mice significant ML burden reduction, as well as degeneration 
and hyalinization of the nurse-cell structure, accompanied by early pericystic fibrosis [11, 12]. In 
addition, antigenic preparations from the different stages of T. spiralis have been used in protec-
tion assays in mice. In this way, adult total extracts and ML total extracts provided protection 
against adult (89–74%) and ML (80%) stages. Importantly, ML total extracts induced the reduc-
tion of female fecundity (74%). The combination of adult and ML total extracts reduced the 
adult and ML load by 96% and 86%, respectively, and 73% reduction in female fecundity [13]. 
Protection assays performed in pigs have explored the use of excretory/secretory (E/S) antigens 
from T. spiralis ML and NBL total extracts [14, 15]. E/S products administered with CFA or 
aluminum hydroxide induced moderate protection mainly directed against the fecundity of 
female worms [14]. On the other hand, NBL killed by freezing and thawing combined with 
CFA were highly protective in swine (78%) against T. spiralis challenge, compared to 40% pro-
tection elicited with E/S products of ML [15]. These assays established that in pigs the immune 
response is mainly directed against fecundity of female worms and to the NBL.
It is worth mentioning that most of the studies have focused on ML antigens. Indeed, ML 
antigens are released and presented to the host immune system twice: by ingested ML in the 
intestine, and again when the new generation of ML becomes resident in muscle cells. Besides, 
ML antigens play an important role in the invasion of intestinal epithelium and therefore in 
the establishment of the infection in muscle cells. Even more, T. spiralis ML surface and E/S 
antigens are recognized by a wide range of hosts [16]. The carbohydrate epitope tyvelose 
confers the immunodominance to surface and E/S ML antigens [17]. Anti-tyvelose antibod-
ies inhibit parasite invasion of an in vitro model of epithelial cells [18, 19]; however, tyvelose 
failed to elicit in mice a protective immune response against the enteral phase of infection [20].
Because of their antigenicity, the protection induced by ML surface and E/S products was 
extensively evaluated in mice [21–23]. In all these assays, partial protection against T. spiralis 
challenge was obtained as assessed by the reduction of adult and ML burden as well as female 
worm fecundity (35–58%).
A further step was achieved with surface and E/S stage-specific antigens purified by spe-
cific monoclonal antibodies [21, 24]. These antigens administered with CFA protected mice 
against parasite challenge, as determined by ML load reduction (29.6 and 50%, respectively). 
Protection induced by purified E/S products (49 and 55 kDa) was similar to that achieved 
when total E/S products were used [21].
Other E/S products, mainly glycoprotein of Mr 53 kDa (gp53) and 43 kDa (gp43), were widely 
investigated as first-generation vaccines. The role of these glycoproteins as mediators of intestinal 
epithelial cell invasion and niche establishment of T. spiralis has been suggested [18]. Even more, 
it was shown that antibodies against these glycoproteins inhibit in the vitro invasion of intestinal 
epithelial by T. spiralis [19]. Therefore, gp43 and gp53 are considered good vaccine candidates.
2.2. Second-generation vaccines
The 40- and 30-mer peptides derived from gp43 were synthesized and tested in protec-
tion assays [25, 26], giving rise to the development of second-generation vaccines against 
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 trichinellosis. The 40- and 30-mer synthetic peptides were administered to mice by intrana-
sal (i.n.) or subcutaneous route with adjuvants such as the subunit B of cholera toxin (CTB) 
or incomplete Freund’s adjuvant (IFA). The 40- and 30-mer synthetic peptides induced a 
significant reduction of adult worm burden against T. spiralis infection in comparison to 
control (36 and 64%, respectively). The immune response was characterized by the produc-
tion of IgG1. Although the use of the synthetic peptides represents an innovative strategy 
for vaccine development, protection induced was not higher than that elicited with crude 
total extracts.
The induction of mucosal immunity plays an important aspect to be considered in the design 
of a blocking-transmission vaccine in which the use of liposomes, viral particles, and bacterial 
carriers has been used to deliver the selected antigen [27–31].
In this regard, Salmonella-based vaccine systems are considered among the most advanced 
and promising technologies developed to induce immunological protection against enteric 
pathogens because of their ability to both colonize the small intestine and invade non-phago-
cytic epithelial cells, thus allowing access to the underlying lymphoid tissue [32]. Taking 
advance of the use of Salmonella as live bacterial carrier, our group developed a Salmonella 
vaccine candidate expressing the 30-mer peptide derived from gp43 (amino acid residues 
210–239, designated as Ag30) from T. spiralis ML. The autotransporter ShdA was employed to 
translocate Ag30 peptide to the surface of S. enterica serovar Typhimurium SL3261 [27]. Mice 
immuzed by i.n. route with the recombinant Salmonella pAg30 elicited a protective immune 
response against T. spiralis challenge, with 61.83% reduction of the adult burden and produc-
tion of antigen-specific IgG1 and IL-5 (Figure 2). The use of the autotransporter MisL has 
also been used to translocate Ag30 to the surface of S. enterica serovar Typhimurium SL3261. 
The immunization of mice with the recombinant vaccine (i.n. route) in combination with an 
intraperitoneal (i.p.) boost with the recombinant protein induced a higher level of protection 
(76%) against the enteral phase of T. spiralis infection [28]. In addition, our group explore the 
use of the 40-mer peptide of T. spiralis gp43 protein (named Ag40) expressed on the surface of 
S. enterica serovar Typhimurium SL3261 using the autotransporter ShdA (Salmonella pAg40). 
Partial protection against T. spiralis infection at the enteral level was induced (47%). The use 
of Salmonella pAg30 together with Salmonella pAg40 did not elicit higher protection against T. 
spiralis infection (58%) [33].
To enhance the humoral and cellular antigen-specific immune response against T. spiralis 
infection, multiple copies of the minimum binding domain of complement C3 component 
(P28) were used as molecular adjuvant. For this, Salmonella pAg30 vaccine was engineered 
to express the Ag30 peptide from T. spiralis fused to three copies of P28 adjuvant (Ag30-P28
3
) 
and was either expressed on the bacterial surface or secreted to the milieu [31]. Salmonella vac-
cines were administered to mice by i.n. route. Data showed that Salmonella strains secreting 
Ag30-P28
3
 or Ag30 reduced the adult worm burden by 92.8 and 72%, respectively, following 
the challenge with T. spiralis ML compared to 42% achieved by recombinant Salmonella dis-
playing Ag30-P28
3
 on the surface (Figure 2). The protection induced by secreted Ag30-P28
3
 
was associated with a mixed Th1/Th2 with predominance of Th2 phenotype, characterized by 
the production of IgG1, intestinal IgA antibodies, and IL-5 secretion.
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Some new surface and E/S proteins from ML (some of them expressed in other stages of the 
parasite) have been identified and their recombinant proteins evaluated as vaccine candi-
dates. The surface protein 28.9 kDa (Ts14-3-3) [34], the E/S protein of 35.5 kDa (TspSP1.2) [35], 
54.7 kDa amino peptidase (TsAP) also expressed by adult worms and NBL, located primarily 
at the cuticle and internal organs of the parasite [36], the protein of 20 kDa (Ts-ES-1) existing 
in the E/S products of T. spiralis adult and ML [37], and paramyosin (Ts-Pmy) [38] among oth-
ers have been tested in mice. In all cases, partial protection assessed against the enteral and 
muscle phase of the infection was elicited (35–55%). Interestingly, a multiple epitope vaccine 
was developed including a highly antigenic epitope of Ts-Pmy (8F7) and an epitope (M7) 
from Ts-87 antigen (present in adult worm). Epitopes were conjugated to KLH and mixed to 
formulate a multi-epitope vaccine. This vaccine induced partial protection (35%) against T. 
spiralis infection in mice [30]. Protection elicited was not higher than that obtained with 8F7 
or M7 alone.
Importantly, it was shown that ML cannot invade the intestinal epithelial cells in vitro cul-
tured unless they are exposed to the intestinal milieu or bile and activated into the intestinal 
infective larvae (IIL) [39–41]. The identification of IIL molecules provides attractive informa-
tion not only to elucidate the mechanism of parasite invasion and immune evasion but also to 
Figure 2. Protection in mice induced by recombinant Salmonella enterica serovar Typhimurium strains against the 
challenge with Trichinella spiralis muscle larvae. Attenuated Salmonella expresses Ag30 or Ag40 derived from the gp43 of 
T. spiralis muscle larvae displayed on the surface of recombinant Salmonella strains. In addition, Ag30 was fused to three 
copies of the molecular adjuvant P28 (Ag30-P28₃) and it was expressed on the bacterial surface or secreted to the medium 
through OmpT protease site (SCOT).
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identify possible molecular targets for vaccine. Following this purpose, several IIL molecules 
have been identified and their protective capacity evaluated. The Tsp10 polypeptide of T. 
spiralis IIL displayed on the surface of T7 phage was injected i.p. and intradermally at differ-
ent sites of the abdomen, and elicited in immunized mice a Th2-protective response against 
parasite challenge, reducing the adult and ML load by 62.8 and 78.6%, respectively [29].
Other proteins with significant higher expression in IIL than in ML such as a putative copper/
zinc superoxide dismutase (SODC), adult-specific DNase II, putative low-density lipopro-
tein receptor domain class A (LDLRA), and secreting receptor (SR) have been identified [41]. 
More recently, some important proteins were identified in E/S from IIL, such as the gp53 kDa 
with serine protease activity, multi-cystatin-like domain and cystatin-like protein, deoxyri-
bonuclease II family protein, among others [42]. The protective evaluation of recombinant 
cystatin-like protein from T. spiralis IIL administered in mice with CFA and boosted with 
recombinant protein with IFA showed 62 and 64% reduction in the number of ML and adult 
worm, respectively. Interestingly, it was recognized by pig antiserum as early as 15 days post 
infection [43].
T. spiralis protein Nudix hydrolase (TsNd) is an up-regulated gene in IIL compared to ML. 
Recombinant TsNd emulsified with CFA displayed in mice a 57.7 and 56.9% reduction in 
adult worms and in ML burden, respectively, after a challenge infection with T. spiralis with 
high IgG1 levels [44].
Although rodent models have provided important knowledge about the immune response 
elicited against T. spiralis and immunogenic molecules recognized by sera from infected 
animals, it is important to mention two important aspects of trichinellosis that should be 
taken into account for the development of a vaccine. First, domestic pork consumption still 
accounts for many trichinellosis outbreaks, mostly in Eastern Europe and Argentina, where 
backyard pigs are raised under high-risk-rearing practices, especially the feeding of food 
waste. Second, a small number of studies have characterized adult antigens that stimulate 
immunity during an early infection and could be effective in host protection. In this way, 
recent studies have identified proteins from adult and ML that are recognized by sera of pigs 
experimentally infected with T. spiralis [45, 46]. Some proteins common from adult and ML 
stage have been identified, among them heat-shock proteins (HSPs), enolase, and 5'-nucleo-
tidase. It was shown that HSP70 and a 38 kDa protein (Ts87) that is present in E/S products 
and on the adult cuticle induced protective immunity in mice assessed by ML burden reduc-
tion (38.4 and 29%, respectively) [46, 47].
It is worth noting that another important aspect that has to be considered is the anti-fecun-
dity effects and immunity to the NBL described in T. spiralis-infected pigs [48]. Therefore, the 
identification of immunogenic proteins characteristic of NBL is important for the induction 
of protection and vaccine development that could be applied in swine. In this regard, an 
immunodominant serine protease, named NBL1, has been identified in NBL, embryos, and 
larvae before birth within the gravid females [49]. Importantly, sera from pigs experimen-
tally infected with Trichinella and pigs immunized with the recombinant C terminal part of 
NBL1 allowed the recognition and identification of six immunodominant linear epitopes on 
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the protein [50]. These epitopes could be used for the development of subunit and multiple 
epitope vaccines.
2.3. Third-generation vaccines
DNA vaccines allow the in vivo expression of antigens in their native conformation, per-
sistent expression of the desired antigen, and the induction of both humoral and cellular 
immunity [51]. Up to date, three DNA vaccines for veterinary use have been licensured 
(against West Nile equine virus, melanoma in dogs, and hematopoietic necrosis virus 
in salmon) [52], encouraging the improvement of experimental DNA vaccines against 
trichinellosis.
Several DNA vaccines using the eukaryotic expression vector pcDNA3.1 have been designed 
against T. spiralis infection and the induced immune response in mice evaluated. The 31 kDa 
E/S antigen of ML (TspE1) and TsNd, an up-regulated gene in IIL compared to ML, have been 
cloned in pcDNA3.1 vector [53, 54]. Recombinant pcDNA3.1-TsNd vaccine conferred higher 
levels of protection against T. spiralis infection in comparison to pcDNA3.1-TsE1. Vaccination 
of mice with pcDNA3.1-TsNd showed 40.44% reduction in worm adults and 53.9% reduction 
in ML burden with the production of a mixed Th1/Th2 systemic immune response and IgA 
production at the mucosal level [54]. In this case, the use of pcDNA3.1/TsNd did not increase 
the protection previously conferred by recombinant TsNd (57.7 and 56.9% reduction in adult 
and ML burden, respectively) [44].
The eukaryotic expression vector pVAX1 has also been used to express different T. spiralis anti-
gens such as macrophage migration inhibitory factor (MIF) of T. spiralis (TsMIF), the protein 
domain of multi-cystatin-type 1 (MCD-1) (TsMCD-1), and the co-expression of TsMIF and 
TsMCD-1. Vaccination of mice with the recombinant vaccines induced low levels of protection 
(23.17% reduction of ML load) [55]. Slightly higher protection was achieved when pVAX1-ubiq-
uitin vaccine was used (37.95%) [56]. In addition, the recombinant vaccines pVAX1-Ts87 and 
pVAX1-TsPmy conferred 9.7 and 46.6% protection against parasite challenge [57, 58]. Higher 
levels of protection (43.8%) were obtained when animals were co-immunized with pVAX1-
Ts87 and recombinant Ts87. In both cases, a Th1/Th2 immune response was induced [57].
To avoid degradation of DNA vaccines by nucleases, the use of live carriers has been inves-
tigated. In this way, pVAX1-Ts87 and pcDNA3.1/TsNd were delivered by S. typhimurium 
strains SL7207 and SL1344, respectively [59, 60]. Mice immunized with Salmonella pcDNA3.1/
TsNd showed higher levels of protection assessed by adult (73.32%) and ML (49.5%) load 
reduction [60]. In this case, higher protection at the enteral level was achieved than with the 
use of the DNA vaccine alone (73.32 vs. 40.44%).
2.3.1. DNA vaccine encoding Ag30
Since DNA vaccines have several advantages over protein vaccines, our research group devel-
oped a DNA vaccine encoding Ag30 using the pVAX1 vector (pVAX1-Ag30). The intramus-
cular administration of 50-μg pVAX1-Ag30 induced 54% reduction of adult burden in mice. 
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The use of Salmonella to deliver pVAX1-Ag30 failed to elicit higher protection levels at the 
intestinal level (22%) (data not published).
The use of liposomes as carriers of plasmid DNA has been used for vaccination purposes in 
various studies, because they act as adjuvants and protect plasmids from the attack of host 
enzymes [61]. It was our interest to assess the protection elicited by lipoplexes formed with 
3-μg pVAXAg30 and cationic liposomes (LLO-LLE plus cholesterol, L-lysyl-octadecanol, and 
L-lysyl eicosanol). The intranasal administration of the lipoplexes induced in mice very low 
levels of protection against T. spiralis infection (7 and 9% reduction of adult and ML burden) 
(data not published).
Second generation Protection % Reference
Recombinant TsPmy ML 36.2 [38]
Recombinant TsNd A 57.7
ML 56.9
[44]
Recombinant Ts87 ML 39.7 [57]
30-mer synthetic peptide (Ag30) A 36 [26]
Salmonella pAg30 A 61.8 [27]
Salmonella pAg30 (secreted) A 72 [31]
Salmonella pAg30-p28
3
 (secreted) A 92.8 [31]
Salmonella pAg30-p28
3 
(surface) A 42 [31]
Phage T7-Tsp10 A 62.8
ML 78.6
[29]
Multi-epitope (Tspmy, TS87) ML 35 [30]
Third generation
pcDNA3.1-TsNd A 40.44
ML 53.9
[54]
pVAX1-Ts87 ML 9.7 [57]
pVAX1-Ag30 A 54 Personal communication
Third generation + carrier
Salmonella pVAX1-TsPmy A 44.8
ML 46.6
[58]
Salmonella pcDNA3.1-TsNd A 73.32
ML 49.5
[60]
Salmonella pVAX1-Ts87 A 29.8
ML 34.2
[59]
Salmonella pVAX1-Ag30 A 22 Personal communication
A, adult; ML, muscle larvae.
Table 1. Protection in mice induced by some second- and third-generation vaccines administered alone or delivered by 
carriers.
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2.3.2. Protection induced by some candidate antigens as second- and third-generation vaccines 
delivered alone or by live carriers
A summary of protection elicited in mice by some candidate antigens proposed as second- 
and third-generation vaccines is presented in Table 1. Antigen and delivery systems are 
critical elements that influence the protection level induced by the candidate vaccines. Some 
antigens such as Ts87 used as second-generation vaccine or as third-generation vaccine deliv-
ered by Salmonella elicit similar protection against T. spiralis infection. In the case of Ag30, it 
improves the protection induced against the enteral stage of T. spiralis when it is administered 
as second-generation vaccine delivered by attenuated Salmonella, particularly when it is fused 
to the molecular adjuvant P28 and secreted to the medium. For TsNd, no differences in pro-
tection are observed with second- and third-generation vaccines; however, it elicits higher 
protection against T. spiralis adult as third-generation vaccine delivered by Salmonella. On the 
other hand, Tsp10, an IIL antigen displayed on the surface of T7 phage, induced the highest 
protection against the systemic stage of T. spiralis; however, at the enteral level the protection 
was lower. An important aspect to mention is the administration route of these candidate vac-
cines that is correlated with the protection elicited against the parasite challenge. The second-
generation vaccine, Salmonella pAg30-p28
3
 (secreted) administered by i.n. route, afforded at 
the intestinal level the highest protection against T. spiralis challenge (92.8%), followed by 
Salmonella pAg30 displayed by MisL (second-generation vaccine) (76%), also administered 
by i.n. route and Salmonella pcDNA3.1-TsNd (third-generation vaccine) (73.2%) administered 
by oral route. On the other hand, Tsp10, an IIL antigen displayed by T7 phage, provided the 
highest protection against T. spiralis ML (78.6%); it was administered by i.p. and intrader-
mal via at multiple sites of mice abdomen. Therefore, the administration route also plays an 
important aspect to be considered in the vaccine development.
3. Adjuvants
The induction of mucosal immunity plays an important aspect to be considered in the 
design of a vaccine against T. spiralis infection. Therefore, it is desirable that vaccine for-
mulations contain adjuvants or immunomodulatory molecules capable to polarize the 
immune response to a Th2-type response. Indeed, adjuvants can influence the balance of 
the induced antibody and cell-mediated immunity so constitute an imperative element of 
modern vaccines [62].
An adjuvant with documented in vitro and in vivo Th2-skewing properties is the cholera 
toxin subunit B (CTB) [63]. CTB has been used as potent immunological adjuvant in the 
induction of protective Th2-type response by first- and second-generation vaccines against 
T. spiralis. More recently, the second-generation vaccine, gp53 of T. spiralis ML, contained 
into virus-like particles with the influenza matrix protein 1 (M1) as a core protein was 
administered to mice together with CTB, inducing protective immunity against the parasite 
challenge [64].
Aluminum hydroxide adjuvant (alum) has also been administered with first- and second-
generation vaccines. When administered with E/S products from T. spiralis ML, although it 
has been documented in mice to induce Th2 responses, no production of IL-5 was detected 
[65].
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The use of the adjuvant water in oil emulsions Montanide® ISA70 (Seppic, France) has been rec-
ommended for administration with first-generation vaccines, since its administration together 
with ML total extracts induced high level of protection (84.5%) against T. spiralis infection [66].
In order to enhance immunity, cytokines genes such as IL-4 have been included into third-
generation vaccines (DNA vaccines) and have demonstrated to evoke a Th2-type response 
[67]. Interestingly, porcine IL-4 has been successfully evaluated as an immunological adjuvant 
in a vaccine candidate against porcine reproductive and respiratory syndrome virus (PRRSV) 
[68]. The cytokine IL-33 plays an important role at the mucosal level, inducing expansion of a 
multipotent progenitor cell population with differentiation into macrophages, basophils, and 
mast cell populations that promote the development of Th2 cytokine responses [69]. Further 
studies are necessary to determine the potential of IL-4 and IL-33 as molecular adjuvants in 
the induction of mucosal-protective immunity against T. spiralis.
4. Perspectives and future directions
4.1. Multi-epitope or polyvalent vaccines against trichinellosis
T. spiralis has a complex life cycle; the immune response elicited by a vaccine based on a 
unique antigen may not be strong enough to combat the challenging infection, and therefore 
multi-epitope vaccines against T. spiralis have been proposed. In this regard, the combination 
of three selected epitopes from Ts-Pmy and Ts87 from T. spiralis adult elicited in immunized 
mice IgG and IgG1 production and higher protection (35%) against the parasite challenge in 
comparison to that induced by individual epitope peptides [47]. To accomplish higher protec-
tive immune responses against T. spiralis, it will be necessary to design a vaccine with multi-
epitopes from different parasite stages focusing on NBL and adult stages.
4.2. Probiotics in protection against T. spiralis infection
It has been demonstrated that probiotics modulate the intestinal environment preventing 
enteric infections. The lactic acid bacteria Lactobacillus is considered as probiotic; they are part 
of the commensal bacteria and contribute to the maintenance of immune homeostasis in the 
gut [70]. The protective role of L. casei against high infection dose of T. spiralis has been demon-
strated in mice inoculated intraperitoneally with the bacteria as assessed by adult (76.7%) and 
ML (80.9%) load reduction, production of high IgA and IgG anti-T. spiralis antibody levels as 
well as IL-4 [71]. More recently, the protection conferred by different Lactobacillus strains, L. casei, 
L. plantarum, and L. acidophilus, against T. spiralis infection was analyzed. The highest protection 
was elicited by L. plantarum, against adult (69.02%) and ML (87.92%). Interestingly, the authors 
demonstrated an amelioration of inflammation and damage in the intestine of T. spiralis-infected 
mice inoculated with L. plantarum with respect to non-treated-infected animals [72]. So far, the 
use of probiotics is considered as a new tool for trichinellosis control.
4.3. Plant-based veterinary vaccine
Plant-based vaccines might be used as edible vaccines for sustainable prophylaxis against vari-
ous important parasitic diseases, including trichinellosis. Recombinant proteins based in plants 
can be produced in nuclear-transformed plants, synthesized in the cytoplasm, and can be accu-
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mulated in different subcellular organelles, or secreted, once an appropriate transit or signal 
peptides are used [73, 74]. Plants are considered an attractive platform for veterinary vaccines, 
due to low-cost production, sterile delivery, and cold storage/ transportation at ambient tem-
perature, compared to traditional attenuated vaccines, which present some inconvenience in 
terms of insufficient mass production, residual toxicity, means of transportation, and safety [75]. 
Antigens administered by oral route are subject to proteolysis in gastrointestinal tract, reduc-
ing their bioavailability, and therefore affecting the quality of immune response. Then, vaccine 
antigens can be protected by plant cell walls from further degradation in the digestive tract, 
enabling them to reach the gut-associated lymphoid tissue [73].
Many species of plants, including tobaccos, alfalfa, spinach, potatoes, rice, beans, maize, 
tomatoes, strawberries, and carrots, can be used in plant biotechnology for the expression 
and production of foreign proteins, remaining stable without the loss of activity for years at 
room temperature. Hence, plants could be suitable for direct consumption and useful for the 
development of animal vaccines [74]. In fact, edible vaccines produced in papaya and corn 
seed induced protection against porcine-cysticercosis (70–90%) and porcine-transmissible 
gastroenteritis virus (50%) [76, 77]. Even more, edible vaccines can include adjuvants as it was 
the case for As16-an antigen protective against the roundworm Ascaris suum fused with CTB 
in transgenic rice seeds, resulting in an antibody response [78].
Plant-based vaccines represent an excellent tool for mass prevention especially at the veteri-
nary field; their use in vaccine development against T. spiralis remains to be explored.
5. Conclusions
Different vaccine candidates based on antigens from different stages of T. spiralis, used as recom-
binant proteins or as DNA vaccines, delivered alone or by live carriers have been proposed. Most 
of them with some exceptions have induced partial protection against the enteral and muscle 
phase of the infection. In these studies, a mixed Th1/Th2 immune response with predominance 
of a Th2 response has been elicited. Up to now, the second-generation vaccines, Salmonella 
pAg30-p28
3
 (secreted) and T7-Tsp10, have afforded at the intestinal and systemic level, respec-
tively, the highest protection against T. spiralis challenge. Protection elicited by the candidate 
vaccines is influenced by the candidate antigen, delivery system, and administration route. 
Importantly, search for more useful vaccine candidates that could elicit high protection against 
T. spiralis infection in pigs is required. These vaccines may include antigens from IIL, NBL, and 
from pre-adult and adult stages of infection, administered alone or as multi-epitope vaccine. The 
use of adjuvants or immunomodulatory molecules capable to polarize the immune response to a 
Th2 type should be taken into account in a way to improve the protection induced by candidate 
vaccines. On the other hand, plant-based vaccines represent an excellent tool that needs to be 
explored in vaccine development against T. spiralis with application at the veterinary field.
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Abbreviations
Ag30 30-mer peptide derived from gp43 from T. spiralis ML
Ag30-P28
3
 Ag30 fused to three copies of P28 adjuvant
Ag40 40-mer peptide derived from gp43 from T. spiralis ML
CTB Cholera toxin subunit B
CFA Complete Freund's adjuvant
E/S Excretion/secretion products
gp43 Glycoprotein with molecular weight of 53 kDa from T. spiralis ML
gp53 Glycoprotein with molecular weight of 43 kDa from T. spiralis ML
HSP70 Heat-shock protein 70
IFA Incomplete Freund’s adjuvant
IIL Intestinal infective larvae
i.n. Intranasal
i.p. Intraperitoneal
KLH Keyhole limpet hemocyanin
ML Muscle larvae
NBL Newborn larvae
P28 Minimum binding domain of complement C3 component
TsAP 54.7 kDa amino peptidase
Ts-ES-1 Protein of 20 kDa existing in the E/S products of T. spiralis adult and ML
Ts14-3-3 Surface protein 28.9 kDa
TsMCD-1 Protein domain of multi-cystatin-type 1 of T. spiralis
Ts-Pmy Paramyosin
Ts87 38 kDa protein that is present in E/S products and on the adult cuticle
TsMIF Macrophage migration inhibitory factor of T. spiralis
TsNd Trichinella spiralis Nudix hydrolase
TspE1 31 kDa E/S antigen of ML
TspSP1.2 E/S protein of 35.5 kDa
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